Press Releases

Lakewood-Amedex Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued a “Notice of Allowance” for two broad patent applications related to the Company’s broad-spectrum antimicrobial Nu-8 Bisphosphocin compound, titled “Antimicrobial Compounds, Compositions, and Uses Thereof....

SARASOTA, Fla., Jan. 17, 2019 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today it had entered into a collaboration agreement with Nassau based Foot and Ankle International (Bahamas) to conduct two Phase 2 cDFU clinical trials for its topically applied Nu-3 antimicrobial used to eliminate...

SARASOTA, Fla., December 4, 2017 - Lakewood-Amedex, Inc., a leading developer of novel anti-infective pharmaceuticals, today announced that it will be advancing a second Bisphosphocin drug candidate, Nu-8, into preclinical IND-enabling studies following pre-IND written communications with the U.S. Food and Drug Administration (FDA). Nu-8 will...

SARASOTA, Fla., Sept. 27, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, today announced it will present at the BioPharm America Conference top-line Phase 1/2a clinical data for its lead program, topically applied Nu-3 antimicrobial, to eliminate infection and promote wound healing in patients...

SARASOTA, Fla., Aug. 22, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today the completion of patient treatment in the final cohort of the Company's Phase 1/2a clinical trial for its lead program, topically applied Bisphosphocin Nu-3 antimicrobial, for patients...